Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01777165 | A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery | PHASE2 | COMPLETED | 240 | — | — | Feb 1, 2013 | Mar 1, 2014 | Jul 7, 2021 | 41 | United States, Denmark |
| Arm | Type | Description |
|---|---|---|
| Arm 1 ABT-719 lower dose | EXPERIMENTAL | - |
| Arm 2 ABT-719 intermediate dose | EXPERIMENTAL | - |
| Arm 3 ABT-719 higher dose | EXPERIMENTAL | - |
| Arm 4 placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ABT-719 | DRUG | 1 arm of ABT-719 higher dose, 1 arm of ABT-719 intermediate dose, and 1 arm ABT-719 lower dose |
| Placebo | DRUG | Placebo infusion |
Inclusion Criteria: * Subject must be male or female, age greater than or equal to 18 years old. * Subjects must have stable renal function, per Investigator discretion and no known increase in serum creatinine of greater than or equal to 0.3 mg during the preceding 4 weeks. * Subjects with estimat...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Fresenius Medical Care AG Sponsored ADR | FMS | 2 | PHASE3 | Dialysis |
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
| CalciMedica, Inc. | CALC | 1 | PHASE2 | Auxora |
| Talphera, Inc. | TLPH | 1 | NA | Undisclosed |
| SeaStar Medical Holding Corporation | ICU | 2 | — | Undisclosed |
| Collegium Pharmaceutical, Inc. | COLL | 1 | — | Flozin |